• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干扰素-γ、氧化型低密度脂蛋白和催乳素血清水平的逆转与围产期心肌病患者的临床改善相关。

Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy.

作者信息

Forster Olaf, Hilfiker-Kleiner Denise, Ansari Aftab A, Sundstrom J Bruce, Libhaber Elena, Tshani Winnie, Becker Anthony, Yip Anthony, Klein Gunnar, Sliwa Karen

机构信息

Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa.

出版信息

Eur J Heart Fail. 2008 Sep;10(9):861-8. doi: 10.1016/j.ejheart.2008.07.005. Epub 2008 Sep 2.

DOI:10.1016/j.ejheart.2008.07.005
PMID:18768352
Abstract

AIM

Peripartum cardiomyopathy (PPCM) is characterized by acute onset of heart failure of unknown aetiology. We aimed to identify mechanisms involved in initiation and progression of the disease.

METHODS AND RESULTS

Serum markers related to cardiac function, apoptosis, oxidative stress, remodelling, inflammation and the nursing hormone prolactin were analyzed in PPCM patients and healthy controls. The kinetics of these markers were compared between patients who improved cardiac function (IMP) and those patients who did not improve (NIMP), over 6 months follow-up. All patients received ACE-inhibitors, beta-blockers and diuretics. Baseline levels of TGF-beta-1 were significantly lower, MMP-9 and VEGF were not different; all other markers were significantly higher in PPCM compared with controls. Only baseline NT-proBNP levels were higher in NIMP compared with IMP. After 6 months, NT-proBNP, oxLDL and IFN-gamma were significantly lower in IMP and the decrease in oxLDL, IFN-gamma and prolactin was significant in IMP but not in NIMP. Significant correlations were observed between the kinetics of NT-proBNP, oxLDL, prolactin and IFN-gamma in PPCM patients.

CONCLUSION

Baseline NT-proBNP and the failure to decrease oxLDL, IFN-gamma and prolactin are associated with poor outcome in PPCM, suggesting a potential role of these factors in the pathophysiology of PPCM and for risk stratification of PPCM patients.

摘要

目的

围产期心肌病(PPCM)的特征是病因不明的急性心力衰竭。我们旨在确定该疾病发生和发展过程中的相关机制。

方法与结果

分析了PPCM患者和健康对照者中与心脏功能、细胞凋亡、氧化应激、重塑、炎症及护理激素催乳素相关的血清标志物。在6个月的随访期间,比较了心功能改善患者(IMP)和心功能未改善患者(NIMP)这些标志物的变化情况。所有患者均接受了血管紧张素转换酶抑制剂、β受体阻滞剂和利尿剂治疗。与对照组相比,PPCM患者的基线转化生长因子β-1水平显著降低,基质金属蛋白酶-9和血管内皮生长因子水平无差异;所有其他标志物水平均显著升高。与IMP组相比,NIMP组仅基线N末端脑钠肽前体水平较高。6个月后,IMP组的N末端脑钠肽前体、氧化型低密度脂蛋白和干扰素-γ显著降低,IMP组氧化型低密度脂蛋白、干扰素-γ和催乳素的降低显著,而NIMP组则不然。在PPCM患者中,观察到N末端脑钠肽前体、氧化型低密度脂蛋白、催乳素和干扰素-γ变化之间存在显著相关性。

结论

基线N末端脑钠肽前体以及氧化型低密度脂蛋白、干扰素-γ和催乳素未能降低与PPCM的不良预后相关,提示这些因素在PPCM病理生理学及PPCM患者风险分层中可能发挥作用。

相似文献

1
Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy.干扰素-γ、氧化型低密度脂蛋白和催乳素血清水平的逆转与围产期心肌病患者的临床改善相关。
Eur J Heart Fail. 2008 Sep;10(9):861-8. doi: 10.1016/j.ejheart.2008.07.005. Epub 2008 Sep 2.
2
Management of a case of peripartum cardiomyopathy.一例围产期心肌病的管理
Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):514-8; quiz 518. doi: 10.1038/ncpcardio0640.
3
Peripartum cardiomyopathy.围产期心肌病
Lancet. 2006 Aug 19;368(9536):687-93. doi: 10.1016/S0140-6736(06)69253-2.
4
Prolactin: a new therapeutic target in peripartum cardiomyopathy.催乳素:围生期心肌病的新治疗靶点。
Heart. 2010 Sep;96(17):1352-7. doi: 10.1136/hrt.2009.179218. Epub 2010 Jul 23.
5
The role of growth hormone replacement in a growth hormone deficient patient with underlying cardiomyopathy and severe congestive heart failure.生长激素替代疗法在一名患有潜在心肌病和严重充血性心力衰竭的生长激素缺乏患者中的作用。
J Heart Lung Transplant. 2005 Jan;24(1):110-4. doi: 10.1016/j.healun.2003.09.035.
6
Experience with beta-blockers in long term management of peripartum cardiomyopathy.
J Ayub Med Coll Abbottabad. 2004 Apr-Jun;16(2):80-1.
7
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.血清皮质醇作为慢性心力衰竭患者心脏事件的有用预测指标:氧化应激的影响
Circ Heart Fail. 2009 Nov;2(6):608-15. doi: 10.1161/CIRCHEARTFAILURE.109.868513. Epub 2009 Sep 28.
8
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.松弛素治疗可促进适应性肥大,但不能预防实验性围产期心肌病中的心力衰竭。
Cardiovasc Res. 2017 May 1;113(6):598-608. doi: 10.1093/cvr/cvw245.
9
Understanding Peripartum Cardiomyopathy.了解围产期心肌病。
Annu Rev Med. 2018 Jan 29;69:165-176. doi: 10.1146/annurev-med-041316-090545. Epub 2017 Aug 16.
10
Circulating microparticles as indicators of peripartum cardiomyopathy.循环微颗粒作为围生期心肌病的指标。
Eur Heart J. 2012 Jun;33(12):1469-79. doi: 10.1093/eurheartj/ehr485. Epub 2012 Feb 3.

引用本文的文献

1
Aims and Rationale of a National Registry Integrating Clinical, Echocardiographic, and Multi-Omics Profiling to Promote Precision Medicine in Peripartum Cardiomyopathy.整合临床、超声心动图和多组学分析以促进围产期心肌病精准医学的国家登记处的目标和基本原理
Biomedicines. 2025 Aug 20;13(8):2026. doi: 10.3390/biomedicines13082026.
2
Gene Analysis of Four Families with Severe Peripartum Cardiomyopathy Reveals Known Gene Mutations and Supports the Recent Call for Screening.对四个重度围产期心肌病家族的基因分析揭示了已知基因突变,并支持近期的筛查呼吁。
Rev Cardiovasc Med. 2024 Nov 14;25(11):399. doi: 10.31083/j.rcm2511399. eCollection 2024 Nov.
3
Precision medicine in peripartum cardiomyopathy: advancing diagnosis and management through genomic and phenotypic integration.
围产期心肌病的精准医学:通过基因组和表型整合推进诊断与管理
Ann Med Surg (Lond). 2024 Jul 1;86(8):4664-4667. doi: 10.1097/MS9.0000000000002329. eCollection 2024 Aug.
4
The Utilization and Interpretation of Cardiac Biomarkers During Pregnancy: Expert Panel.孕期心脏生物标志物的应用与解读:专家小组
JACC Adv. 2022 Aug 26;1(3):100064. doi: 10.1016/j.jacadv.2022.100064. eCollection 2022 Aug.
5
Interferons and interferon-related pathways in heart disease.心脏病中的干扰素及干扰素相关通路
Front Cardiovasc Med. 2024 Apr 11;11:1357343. doi: 10.3389/fcvm.2024.1357343. eCollection 2024.
6
Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found.围生期心肌病的生物标志物:已知与未知。
Biomolecules. 2024 Jan 12;14(1):103. doi: 10.3390/biom14010103.
7
NT-proBNP-Possible Prognostic Marker in Pregnant Patients with Associated Cardiovascular Risk Factors and SARS-CoV-2 Infection.NT-proBNP——伴有心血管危险因素和SARS-CoV-2感染的孕妇可能的预后标志物。
Diagnostics (Basel). 2023 Sep 23;13(19):3032. doi: 10.3390/diagnostics13193032.
8
Serum Proteomic Analysis of Peripartum Cardiomyopathy Reveals Distinctive Dysregulation of Inflammatory and Cholesterol Metabolism Pathways.围产期心肌病的血清蛋白质组学分析揭示了炎症和胆固醇代谢途径的独特失调。
JACC Heart Fail. 2023 Sep;11(9):1231-1242. doi: 10.1016/j.jchf.2023.05.031. Epub 2023 Aug 2.
9
Peripartum Cardiomyopathy: Risks Diagnosis and Management.围产期心肌病:风险、诊断与管理
J Multidiscip Healthc. 2023 May 3;16:1249-1258. doi: 10.2147/JMDH.S372747. eCollection 2023.
10
Catastrophic presentation of peripartum cardiomyopathy: a case report of a challenging diagnosis.围产期心肌病的灾难性表现:一例诊断困难的病例报告
Eur Heart J Case Rep. 2022 Sep 23;6(10):ytac395. doi: 10.1093/ehjcr/ytac395. eCollection 2022 Oct.